Potent interleukin 3 receptor agonist with selectively enhanced hematopoietic activity relative to recombinant human interleukin 3.

@article{Thomas1995PotentI3,
  title={Potent interleukin 3 receptor agonist with selectively enhanced hematopoietic activity relative to recombinant human interleukin 3.},
  author={Joylene W. L. Thomas and Charles M. Baum and William F. Hood and Birgit Klein and Joseph B. Monahan and K Paik and Nicholas R Staten and Marc Abrams and J P Mckearn},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={1995},
  volume={92 9},
  pages={3779-83}
}
A systematic evaluation of structure-activity information led to the construction of genetically engineered interleukin 3 (IL-3) receptor agonists (synthokines) with enhanced hematopoietic potency. SC-55494, the most extensively characterized member of this series, exhibits 10- to 20-fold greater biological activity than recombinant human IL-3 (rhIL-3) in human hematopoietic cell proliferation and marrow colony-forming-unit assays. In contrast, SC-55494 is only twice as active as rhIL-3 in… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Thrombopoietic factors in chronic bone marrow failure states: the platelet problem revisited.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2005

Receptor binding kinetics of human IL-3 variants with altered proliferative activity.

Biochemical and biophysical research communications • 2001
View 1 Excerpt

Similar Papers

Loading similar papers…